Rallybio Corporation reported its financial results for the third quarter of 2025, revealing a net income of $16.0 million, a significant turnaround from a net loss of $11.5 million in the same period last year. The company attributed this positive shift primarily to a gain of $22.4 million from the sale of its interest in a joint venture, which was completed in July 2025. Total revenue for the quarter was $212,000, a slight decrease from $299,000 in the prior year, while collaboration and license revenue increased marginally to $636,000 for the nine months ended September 30, 2025, compared to $598,000 for the same period in 2024.
Operating expenses for the third quarter decreased to $7.1 million from $12.4 million in the previous year, driven by reduced research and development costs, which fell to $4.1 million from $8.2 million. This reduction was largely due to the discontinuation of the RLYB212 program for fetal and neonatal alloimmune thrombocytopenia (FNAIT) and a decrease in personnel-related expenses following a workforce reduction earlier in the year. General and administrative expenses also declined to $3.0 million from $4.1 million, reflecting lower headcount and associated costs.
Rallybio's total assets as of September 30, 2025, stood at $67.7 million, with cash and cash equivalents amounting to $32.1 million, up from $13.9 million at the end of 2024. The company’s marketable securities decreased to $27.2 million from $51.6 million, indicating a strategic shift in asset allocation. The company reported an accumulated deficit of $296.1 million, reflecting ongoing investments in research and development without any commercialized products to date.
In terms of strategic developments, Rallybio has focused on its lead program, RLYB116, a complement component 5 (C5) inhibitor, which is currently undergoing a confirmatory pharmacokinetic and pharmacodynamic study. The company expects to report data from this study in the fourth quarter of 2025. Additionally, Rallybio has entered into a collaboration agreement with Johnson & Johnson to advance research into products addressing unmet needs related to FNAIT, although the company has discontinued its RLYB212 program due to insufficient efficacy data.
Looking ahead, Rallybio anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations through 2027. However, the company acknowledges the need for substantial additional capital to support the development and commercialization of its product candidates. The management remains focused on advancing its clinical programs while navigating the complexities of the biotechnology landscape, including potential regulatory approvals and market competition.
About Rallybio Corp
Rallybio is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Its pipeline includes product candidates targeting maternal-fetal blood disorders, complement dysregulation, hematology, and metabolic conditions. The company leverages scientific expertise, innovative drug design, and strategic collaborations to create transformative, patient-friendly treatments with high unmet medical needs, aiming to improve outcomes for underserved patient populations worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.